Literature DB >> 1620141

Impairment of high-contrast visual acuity in Parkinson's disease.

R D Jones1, I M Donaldson, P L Timmings.   

Abstract

Several studies have shown that the visual system is affected in Parkinson's disease (PD) with reduced contrast sensitivity, low-contrast acuity, and flicker sensitivity, as well as altered electroretinograms (ERGs) and pattern visual evoked potentials (VEPs). Apparently, however, no study has yet specifically determined whether visual acuity to high-contrast stimuli is impaired in PD. Visual acuity was measured in a group of 16 patients with PD, both on and off drugs (for 24 h), and 16 age- and sex-matched normal control subjects. Acuity was impaired in the PD group both on standard Snellen chart and on a screen in a computerized test of visual resolution. The degree of impairment was 24 and 25%, respectively, in the two tests. The PD patients had marginally better acuity on both tests while receiving drugs, but the differences were not significant. The difference between the two groups was consistent with impaired resolution and could not be accounted for by any perceptual dysfunction that may also have been present in the PD group. Conversely, however, impaired acuity may be implicated in studies that have reported mild deficits of visuospatial/visuoperceptual function in PD. Reduced acuity appears to be a subtle sequela of dopaminergic deficiency in the visual system.

Entities:  

Mesh:

Year:  1992        PMID: 1620141     DOI: 10.1002/mds.870070308

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  17 in total

1.  Two-dimensional tracking tasks for quantification of sensory-motor dysfunction and their application to Parkinson's disease.

Authors:  R W Watson; R D Jones; N B Sharman
Journal:  Med Biol Eng Comput       Date:  1997-03       Impact factor: 2.602

2.  Retina as a Model to Study In Vivo Transmission of α-Synuclein in the A53T Mouse Model of Parkinson's Disease.

Authors:  Najiba Mammadova; Thierry Baron; Jérémy Verchère; Justin J Greenlee; M Heather West Greenlee
Journal:  Methods Mol Biol       Date:  2021

3.  Visual dysfunction in patients with Parkinson's disease and essential tremor.

Authors:  Ivanka Štenc Bradvica; Mario Bradvica; Suzana Matić; Patricia Reisz-Majić
Journal:  Neurol Sci       Date:  2014-08-28       Impact factor: 3.307

Review 4.  [The eye as a window to the pathophysiology in Parkinson's syndromes].

Authors:  J Kassubek; A Danek; K Del Tredici-Braak; M W Greenlee; E H Pinkhardt
Journal:  Nervenarzt       Date:  2013-08       Impact factor: 1.214

5.  Reduced macular thickness and macular vessel density in early-treated adult patients with PKU.

Authors:  Csilla Serfozo; Andras Gellert Barta; Endre Horvath; Csaba Sumanszki; Bela Csakany; Miklos Resch; Zoltan Zsolt Nagy; Peter Reismann
Journal:  Mol Genet Metab Rep       Date:  2021-05-05

6.  Visual symptoms in Parkinson's disease.

Authors:  R A Armstrong
Journal:  Parkinsons Dis       Date:  2011-05-25

7.  Contrast Acuity With Different Colors in Parkinson's Disease.

Authors:  Harsh V Gupta; Nan Zhang; Erika Driver-Dunckley; Shyamal H Mehta; Thomas G Beach; Charles H Adler
Journal:  Mov Disord Clin Pract       Date:  2019-09-06

Review 8.  The optic nerve: a "mito-window" on mitochondrial neurodegeneration.

Authors:  Alessandra Maresca; Chiara la Morgia; Leonardo Caporali; Maria Lucia Valentino; Valerio Carelli
Journal:  Mol Cell Neurosci       Date:  2012-08-15       Impact factor: 4.314

9.  Perimetric and retinal nerve fiber layer findings in patients with Parkinson's disease.

Authors:  Evangelia E Tsironi; Anna Dastiridou; Andreas Katsanos; Efthymios Dardiotis; Stella Veliki; Gianna Patramani; Fani Zacharaki; Stella Ralli; Georgios M Hadjigeorgiou
Journal:  BMC Ophthalmol       Date:  2012-10-02       Impact factor: 2.209

10.  Driving under low-contrast visibility conditions in Parkinson disease.

Authors:  E Y Uc; M Rizzo; S W Anderson; E Dastrup; J D Sparks; J D Dawson
Journal:  Neurology       Date:  2009-10-06       Impact factor: 11.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.